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Abstract There is substantial clinical and experimental evi-
dence that ammonia is a major factor in the pathogenesis of
hepatic encephalopathy. In the article is demonstrated that in
hepatocellular dysfunction, ammonia detoxification to gluta-
mine (GLN) in skeletal muscle, brain, and likely the lungs, is
activated. In addition to ammonia detoxification, enhanced
GLN production may exert beneficial effects on the immune
system and gut barrier function. However, enhanced GLN
synthesis may exert adverse effects in the brain (swelling of
astrocytes or altered neurotransmission) and stimulate catab-
olism of branched-chain amino acids (BCAA; valine, leucine,
and isoleucine) in skeletal muscle. Furthermore, the majority
of GLN produced is released to the blood and catabolized in
enterocytes and the kidneys to ammonia, which due to liver
injury escapes detoxification to urea and appears in peripheral
blood. As only one molecule of ammonia is detoxified in
GLN synthesis whereas two molecules may appear in GLN
breakdown, these events can be seen as a vicious cycle in
which enhanced ammonia concentration activates synthesis of
GLN leading to its subsequent catabolism and increase in
ammonia levels in the blood. These alterations may explain
why therapies targeted to intestinal bacteria have only a lim-
ited effect on ammonia levels in patients with liver failure and
indicate the needs of new therapeutic strategies focused on
GLN metabolism. It is demonstrated that each of the various
treatment options targeting only one the of the ammonia-
lowering mechanisms that affect GLN metabolism, such as
enhancing GLN synthesis (BCAA), suppressing ammonia
production from GLN breakdown (glutaminase inhibitors
and alpha-ketoglutarate), and promoting GLN elimination
(phenylbutyrate) exerts substantial adverse effects that can
be avoided if their combination is tailored to the specific needs
of each patient.
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Introduction
Hepatic encephalopathy (HE) results from impaired detoxifi-
cation capacity of the liver leading to accumulation of various
substances that may have deleterious effects on the function of
the central nervous system. A key role in the development of
HE has generally been ascribed to ammonia. Accumulation of
ammonia in the brain results in alterations in activities of
important enzymes, swelling of astrocytes, redistribution of
cerebral blood flow and metabolism from cortical to sub-
cortical areas, and imbalance of neural transmission (Bosoi
and Rose 2009; Felipo and Butterworth 2002).
Although it is clear that the major cause of HE is the accu-
mulation of ammonia, and various treatment strategies are at the
clinician’s disposal, many patients with liver injury die due to the
resulting hepatic coma. Current treatment of HE is mainly aimed
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at reducing the production and intestinal absorption of ammonia
by antibiotics, and non-absorbable disaccharides. However, there
is plenty of evidence that the main source of ammonia is not
intestinal bacteria and that the crucial role in pathogenesis of
hyperammonemia has glutamine (GLN) catabolism in
enterocytes that is delivered to the intestine by the blood stream
(Olde Damink et al. 2002; Nance and Kline 1971).
The first aim of this article is to review alterations in GLN
synthesis and breakdown in liver failure and their relationship to
the development of hyperammonemia and HE. The second aim
is to discuss positive and negative aspects of various treatment
strategies of hyperammonemia focused on GLN metabolism.
GLN and ammonia metabolism in the physiological state
GLN is unique amino acid serving as a “nitrogen shuttle” among
organs, as a preferred respiratory fuel for rapidly proliferating
cells, such as immune cells and enterocytes, a regulator of acid
base balance through production of urinary ammonia, and
playing important signaling role in many process, including
expression of genes, cytokine and hormone production, and
cell proliferation. During stress illness the body’s requirements
for GLN frequently exceed the individual’s ability to synthe-
size sufficient amounts of this amino acid (Hardy and Hardy
2008; Wernerman 2011). Therefore, GLN is classified as a
“conditionally essential” amino acid in the critically ill, the
replacement of which is a rational therapeutic approach in
GLN-deficient states.
There is ingenious cooperation of various tissues in the
synthesis and breakdown of GLN in order to keep low
(<40 μmol/l) concentrations of ammonia in the systemic
circulation and to deliver carbon and nitrogen to rapidly
proliferating cells (Fig. 1). GLN is synthesized de novo from
glutamate and ammonia in a process catalyzed by glutamine
synthetase (GS):
GS reaction : Gluþ NHþ4 þ ATP → GLNþ ADPþ Pi þ Hþ
GS is present in almost all tissues. Substantial activity is in
the brain, heart, and perivenous hepatocytes. However, the
main GLN producer in the body is skeletal muscle because of
its large mass relative to other GS containing organs
(Huizenga et al. 1996). Appreciable GS activity and the po-
tential to release GLN have also the lungs; however, their
contribution to whole body GLN production in humans is
not clear (Cooper and Freed 2005).
GLN released from the skeletal muscle and brain into
circulation is metabolized predominantly in enterocytes,
immunocytes, periportal hepatocytes, and in the kidneys in
the glutaminase (GA) reaction to ammonia and glutamate. The
latter may be metabolized to α-ketoglutarate (α-KG) and
ammonia by the glutamate dehydrogenase (GDH) reaction.
Thus, two ammonia molecules may be produced from one
molecule of GLN:
GA reaction : GLNþ H2O → glutamateþ NH4þ
GDH reaction : glutamate→ αKG þ NH4þ
Ammonia produced in the intestine is carried by portal
blood to the liver, where most of it is extracted by the
periportal hepatocytes and detoxified in the urea cycle. Am-
monia not utilized in ureagenesis is detoxified by perivenous
hepatocytes through amidation of glutamate in the GS reac-
tion. The importance of hepatic extraction of gut-derived
ammonia is demonstrated by the fact that ammonia concen-
trations in systemic circulation are 5–20 times lower than that
of portal blood (Walker 2009).
The kidneys take up GLN from the blood at an amount that
equals 10–15 % of whole-body GLN flux by both the luminal
and antiluminal tubule surfaces and subsequently distributes
the ammonia produced fromGLN between the urine and renal
vein (van de Poll et al. 2004). Physiologically, approximately
70 % of the ammonia generated in the kidneys is released to
the renal vein, and the remainder is excreted in urine (van de
Poll et al. 2004). Presumably, most of the ammonia that
Fig. 1 The role of GLN in
ammonia detoxification in
physiological state. The most of
endogenous GLN is synthesized
from glutamate and ammonia in
the brain, skeletal muscle, and
likely the lungs. GLN released to
the circulation is catabolized in
enterocytes, kidneys, and liver to
ammonia, and this is detoxified to
urea in the liver or excreted
together with urea in the urine
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appears physiologically in the systemic circulation is derived
from GLN metabolism in the kidneys.
GLN and ammonia metabolism in liver injury
When the capacity of the liver to detoxify ammonia in the urea
cycle is not sufficient, GLN synthesis from ammonia in ex-
trahepatic tissues is activated. Elevated concentrations of
GLN can be detected in the blood and in various tissues,
especially in disorders of the urea cycle (Maestri et al.
1992) and in acute liver failure (Clemmesen et al.
2000). The stimulatory effect of hyperammonemia on
GLN synthesis has been demonstrated in skeletal muscle
(Clemmesen et al. 2000; Girard and Butterworth 1992;
Holecek et al. 2011) and in the brain (Norenberg et al.
2005). The lungs may also be important, because their
convenient anatomical position may remove gut-derived am-
monia from the blood before its entrance to the systemic
circulation.
The studies dealing with the effects of GLN supplementa-
tion have demonstrated that enhanced GLN availability in-
creases both GA activity in enterocytes and the portal load of
ammonia (Salloum et al. 1990; Souba et al. 1990). Patients
with liver cirrhosis exert increased intestinal GA activity that
correlates with minimal HE (Romero-Gómez et al. 2004).
Enhanced GLN availability also activates ammonia produc-
tion in the kidneys (Tietze et al. 1992; Gougoux et al. 1985)
and it is clear that the kidneys serves to lower the blood
ammonia concentration during hyperammonemia by increas-
ing urine ammonia excretion (Owen et al. 1961). Unfortunate-
ly, the capability of the kidneys to enhance the urinary excre-
tion of ammonia is limited. During severe liver insufficiency,
ammonia disposal capacity appears to be exceeded and the
kidneys increase ammonia release to the renal veins (Dejong
et al. 1993).
These findings of enhanced ammonia detoxification in
tissues with high GS activities and enhanced GLN breakdown
to ammonia in tissues with high GA activity suggests activa-
tion of GLN-ammonia cycling among tissues and that the
main source of ammonia in patients with liver disease is
catabolism of GLN of endogenous origin in enterocytes and
the kidneys (Fig. 2).
As only one molecule of ammonia is detoxified to GLN in
GLN synthetase reaction, whereas two ammonia molecules
may appear from gradual breakdown of GLN in GA and GD
reactions in the gut and the kidneys, these events can be seen
as a vicious cycle. Enhanced ammonia concentration due to
impaired detoxification to urea in the liver activates synthesis
of GLN in skeletal muscle and in the brain leading to en-
hanced GLN catabolism to ammonia in enterocytes and the
kidneys, and to subsequent increase in ammonia levels in the
blood (Fig. 3).
Adverse effects of enhanced ammonia detoxification
to GLN
Enhanced rates of GLN synthesis in muscle, brain, and proba-
bly in the lungs is undoubtedly a useful response that enables
the body, at least temporarily, to suppress the rise of ammonia in
liver failure. Beside ammonia detoxification, enhanced GLN
production may provide other beneficial effects. There is evi-
dence that GLN is an essential fuel for enterocytes and that
enhanced GLN availability may be of benefit for the barrier
function of the intestine (Meritt et al. 1989). Enhanced GLN
levels may also favorably affect the immune system, glucose
production in the kidneys, and protein balance in skeletal
muscle (Stumvoll et al. 1999). Unfortunately, enhanced rates
of ammonia detoxification to GLN may exert serious adverse
effects–especially in the brain and skeletal muscle.
Adverse effects in the brain The role of alterations of GLN
metabolism induced by hyperammonemia in pathogenesis of HE
has been reviewed in a number of excellent articles (Norenberg
et al. 2005; Albrecht et al. 2010; Lockwood et al. 1984; Suárez
et al. 2002). In short, in the brain, there is a neuron-glialmetabolic
interaction known as glutamate-GLN cycle that maintains low
extracellular concentrations of glutamate and protects neurons
from the deleterious effects of ammonia (Daikhin and Yudkoff
2000). Hyperammonemia enhances ammonia extraction by the
brain, increases GS activity in astroglial cells located in
glutamatergic areas, and thus leads to enhanced accumulation
of GLN in astrocytes (Fig. 4). There is strong evidence that GLN
accumulation in astrocytes contributes to the cerebral edema
observed in acute hyperammonemia and to the presence of
Alzheimer type II astrocytes in chronic hyperammonemia
(Albrecht et al. 2010; Dolman et al. 1988). In addition, enhanced
GLN synthesis may alter the availability of glutamate, an excit-
atory amino acid neurotransmitter and, due to stimulatory effect
of GLN on the uptake of large neutral amino acids across the
blood–brain barrier (Cangiano et al. 1983), participate in the
pathogenesis of brain amino acid imbalance reported in patients
with HE (Fischer and Baldessarini 1971).
Adverse effects in skeletal muscle Hyperammonemia signifi-
cantly increases GS activity and GLN synthesis from gluta-
mate in skeletal muscle (Girard and Butterworth 1992). To
ensure the continuous detoxification of ammonia to GLN, it is
inevitable that glutamate becomes more available. The main
source of amino nitrogen for synthesis of glutamate from α-
ketoglutarate (α-KG) in skeletal muscle is branched-chain
amino acids (BCAA; valine, leucine, and isoleucine). Because
the BCAA aminotransferase reaction is reversible and near
equilibrium, enhanced glutamate consumption activates glu-
tamate synthesis from α-KG and BCAA catabolism (Fig. 5).
The loss of BCAA from cytosol is compensated by their
influx from extracellular fluid, presumably by the exchange
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of BCAA with GLN via L-transporter system (Meier et al.
2002).
These metabolic alterations explain the pathogenesis of the
BCAA deficiency in liver cirrhosis that was enigmatic for
many years. Enhanced rates of BCAA catabolism have been
demonstrated in ammonia infused and cirrhotic rats, and in
patients with liver cirrhosis (Leweling et al. 1996; Holecek
et al. 1996b; Holecek et al. 2000; McCullough et al. 1992).
Recently, clear evidence that hyperammonemia decreases the
BCAA concentration in extracellular fluid was provided using
isolated skeletal muscle (Holecek et al. 2011).
Together with increased levels of aromatic amino acids
(phenylalanine, tyrosine, and tryptophan), decreased levels
of BCAA in blood plasma have been implicated in the “false
neurotransmitter” hypothesis as a possible cause of hepatic
encephalopathy. Fischer and Baldessarini postulated that due
to the decreased concentrations of BCAA, the aromatic amino
acids flood the central nervous system and cause an imbalance
in the synthesis of dopamine, noradrenaline and serotonin
and/or may cause formation of “false neurotransmitters” such
as octopamine, phenylethanolamine and tyramine (Fischer
and Baldessarini 1971).
Therapeutic perspectives
The data mentioned above demonstrate the importance of GLN
in the pathogenesis of hyperammonemia in liver injury and that
some effects of enhanced GLN-ammonia cycling among tissues
are apparently beneficial, but others are detrimental.
Positive effects: - ammonia detoxification
- improves gut barrier function
- improves the function of immune system
Negative effects: - ammonia production from GLN in the gut and
kidneys
- swelling of astrocytes, altered neurotransmission
- decrease of BCAA in extracellular fluid
The existence of a vicious cycle in which GLN produced
from ammonia in skeletal muscle and brain is used for synthesis
of ammonia in enterocytes and the kidneys may explain why
traditional gut-targeted therapies of HE to suppress ammonia
production by bacteria in the colon, such as non-absorbable
disaccharides and antimicrobial drugs, have only limited effects
(Als-Nielsen et al. 2004). Therefore, theoretically, to develop
effective strategies for treating of hyperammonemia and
HE, the good effects of enhanced GLN-ammonia cycling
should be supported and the evil effects eliminated. This
could be achieved by various nutritional and pharmacolog-
ical interventions.
GLN restriction GLN administration to patients with liver cir-
rhosis raises the level of ammonia in the blood. This phenome-
non is used as an oral GLN challenge test for the diagnosis of
subtle neurological deficits and to predict the risk of episodes of
HE in the condition referred to as minimal HE (Oppong et al.
1997; Ortiz et al. 2005). Therefore, GLN intake in patients with
Fig. 2 The role of GLN in
ammonia detoxification in liver
failure. In liver failure, ammonia
escapes the urea cycle and is
detoxified to GLN in the brain,
skeletal muscle, and lungs.
Enhanced GLN availability leads
to enhanced GLN catabolism to
ammonia in enterocytes and the
kidneys. Thus GLN-ammonia
cycling among tissues is
activated. PSS Portal-systemic
shunts
Liver injury  
 breakdown  
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and kidneys  
   
in blood 
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Fig. 3 Supposed vicious cycle in GLN synthesis and breakdown in
pathogenesis of hyperammonemia in liver injury. Enhanced ammonia
concentration due to impaired detoxification to urea in the liver activates
GLN synthesis in skeletal muscle and in the brain leading to enhanced
GLN catabolism to ammonia in enterocytes and the kidneys, and to
subsequent increase in ammonia levels in the blood
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liver disease and HE should be restricted to suppress ammonia
production in the gut. When the diet is otherwise adequate, the
organism may synthesize large amounts of GLN unless the
patient is severely malnourished and has a very low muscle
mass. However, as GLN content is high in most food, its restric-
tion is applicable only in patients fed by artificial diet formulas.
Glutamate The first study reporting success in relieving coma
using glutamic acid was published by Walshe in 1953, who
demonstrated a return of consciousness after sodium glutamate
administration in five episodes of coma in three patients with
subacute or chronic liver injury (Walshe 1953). Since then,
several reports have appeared on the use of glutamic acid,
glutamate, and/or gamma-ethylester of glutamic acid in the treat-
ment of high blood ammonia levels with conflicting results
(McDermott et al. 1955; Santagati et al. 1979; Marchina et al.
1979).
It has been assumed that the effect of glutamate in the
treatment of HE lies in its key role in binding ammonia to
form GLN (Walshe 1953). However, there are studies dem-
onstrating that the intestinal mucosa preferentially metabo-
lizes glutamate as a source of energy and very small changes
in plasma glutamate have occurred after adding large quanti-
ties of glutamate to the food (Stegink et al. 1982; Tsai and
Huang 2000). Therefore, more likely is that oral glutamate
administration decreases blood ammonia indirectly by sparing
catabolism of endogenous GLN in enterocytes. This sugges-
tion is supported by findings of decreased intestinal GA
activity and increased plasma GLN concentrations after
monosodium glutamate supplementation (Boutry et al. 2011).
α-Ketoglutarate α-Ketoglutarate (α-KG) is the precursor of
glutamate and GLN in the intermediate metabolism. When
14C(U)α-KGwas parenterally administered to rats, radioactivity
was recovered in GLN in the kidneys, intestinal mucosa, and
skeletal muscle (Vaubourdolle et al. 1988). The rationale for α-
KG in the treatment of hyperammonemia is also subnormal α-
KG levels in patients with urea cycle disorders and portal-
systemic encephalopathy (Batshaw et al. 1980). Of particular
note is the extensive oxidation of α-KG by enterocytes that may
suppress GLN catabolism and ammonia production by intestinal
cells (Yao et al. 2012). The adverse side effect of α-KG admin-
istration may be catabolism of BCAA as demonstrated by in-
creased levels of branched-chain keto acids in hemodialysis
patients (Riedel et al. 1996).
Unfortunately, there are no studies evaluating the effect of
α-KG in patients with hyperammonemia. Parenteral α-KG
prevented the decrease in GLN in skeletal muscle after surgery
(Hammarqvist et al. 1991). The decrease in ammonia levels
(but without beneficial effects on the treatment of coma) was
demonstrated after ornicetil (ornithine-α-KG) infusion in var-
ious forms of hepatic disease by Chainuvati et al. (1977).
BCAA The peak of research in the field of BCAA use in HE
treatment belongs to the period of extensive work of Fischer’s
group, who demonstrated that BCAA administration normal-
izes amino acid imbalance in plasma, thus reducing the influx
of aromatic amino acids (phenylalanine, tyrosine, and trypto-
phan) to the brain, and consequently improving alterations in
neurotransmitter synthesis (Fischer and Baldessarini 1971;
Fischer et al. 1976). Unfortunately, the enthusiasm for the
BCAA dwindled in 1990s, when large clinical trials failed to
confirm the efficacy of BCAA in HE treatment (Als-Nielsen
et al. 2003). An updated systematic review on the effects of
oral BCAA compared with control supplements or placebo for
patients with cirrhosis and recurrent overt or minimal HE
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Fig. 5 Effects of hyperammonemia on GLN and BCAA metabolism in
skeletal muscle (Holecek et al. 2011). Hyperammonemia enhances GLN
synthesis that may enhance the consumption of BCAA, resulting in their
deficiency in extracellular fluid. BCAA deficiency may participate in the
pathogenesis of muscle wasting and HE. 1 branched-chain aminotrans-
ferase; 2 branched-chain α-ketoacid dehydrogenase; 3 GLN synthetase.
ECF The extracellular fluid; BCAA Branched-chain amino acids; BCKA
Branched-chain keto acids; BCA-CoA Branched-chain acyl-CoA; αnKG




















Fig. 4 Effects of hyperammonemia on GLN metabolism in the brain.
Enhanced GLN synthesis may cause edema in astrocytes, alterations in
availability of excitatory neurotransmitter glutamate, and amino acid im-
balance in the brain. AA Amino acids; GA Glutaminase; GLN Glutamine;
Glu Glutamate; GS Glutamine synthetase
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showed that BCAA supplements improve manifestations of
HE but have no effect on survival (Gluud et al. 2013).
It can be hypothesized that BCAA might be more effective
in patients with marked depression of BCAA. However, a
serious problem in many trials evaluating the effectiveness
of BCAA is the lack of information about alterations in
aminoacidemia. An increase in BCAA levels has been ob-
served in acute injury or in the case of acute decompensation
of liver disease (Rosen et al. 1977; Hehir et al. 1985; Holecek
et al. 1996a; Holecek et al. 1999).
The BCAAmay also ameliorate HE by their positive effects
on protein balance and stimulatory effects on ammonia detox-
ification to GLN in skeletal muscle (Ruderman and Berger
1974; Odessey et al. 1974; Jia et al. 2013). Unfortunately,
enhanced ammonia production from GLN breakdown in the
intestine and the kidneys may later exert harmful effects on the
development of hepatic encephalopathy (Holecek 2013). The
increase in blood ammonia after BCAA supplementation has
been demonstrated both in patients with cirrhosis and healthy
subjects (MacLean et al. 1996; Dam et al. 2011).
GA inhibitors GA inhibitors are expected to preferentially
block ammonia generation by GA in the intestine that seems
to be the main cause of systemic hyperammonemia in cir-
rhotics (Romero-Gómez et al. 2004). A promising compound
is THDP-17, which inhibited GA in cell cultures of colon
carcinoma (Diaz-Herrero et al. 2012). However, GA inhibitors
have potentially harmful effects on the function of enterocytes
and immune cells that use GLN not only for synthesis of
nucleic acids but also as important respiratory fuel
(Windmueller and Spaeth 1980; Tjader et al. 2007). Therefore,
GA inhibitors should reduce GA activity only partially. Fa-
vorable effects may obtain with simultaneous administration
of GA inhibitors and α-KG that may replace GLN as an
energy source in enterocytes (Yao et al. 2012).
Phenylbutyrate/phenylacetate After ingestion, phenylbuty-
rate is rapidly oxidized to phenylacetate, which is conjugated
to GLN to yield phenylacetylglutamine in the liver and
kidneys. Phenylacetylglutamine is then quantitatively excret-
ed by the urine. Removal of GLN from the bodymay suppress
ammonia production from GLN and promote ammonia de-
toxification in the GS reaction. Sodium phenylbutyrate is
effective in the clinical management of hyperglutaminemia
and hyperammonemia in patients with urea cycle disorders
(Brusilow 1991; Enns et al. 2007). A new investigational
agent for treating of HE containing no sodium and having
favorable palatability is glycerol phenylbutyrate. The results
of clinical studies suggest that glycerol phenylbutyrate can be
administered safely to cirrhotic subjects and has the potential
to lower blood ammonia (McGuire et al. 2010).
The obvious risk of enhanced GLN removal from the body
by phenylbutyrate/phenylacetate treatment is GLN depletion,
which may exert adverse effects on the body, such as impaired
immune response and gut integrity. GLN depletion may also
activate BCAA catabolism and suppress BCAA levels as
observed in phenylbutyrate-treated patients with urea cycle
disorders (Scaglia et al. 2004) and thus exert deleterious
effects on the course of HE development.
As a novel treatment of hyperammonemia and HE that seems
to have a more complex way of action is combined administra-
tion of ornithine and phenylacetate (OP). Ornithine is believed to
increase ammonia fixation into GLN and GLN is subsequently
thought to react with phenylacetate forming phenylacety-
lglutamine which is excreted in urine (Jalan et al. 2007). In bile
duct ligated cirrhotic rats, OP treatment reduced arterial ammonia
concentration and increased that of GLN 30 min after treatment
but not after 15 h (Dadsetan et al. 2013). A progressive drop in
ammonia and GLN in blood plasma and a rise of
phenylacetlyglutamine in urine were demonstrated when OP
was administered to cirrhotic patients after an episode of upper
gastrointestinal bleeding (Ventura-Cots et al. 2013).
Conclusions
Hepatocellular dysfunction results in impaired hepatic clear-
ance of ammonia that is detoxified to GLN in the skeletal
Table 1 Adverse effects of indi-
vidual treatment options of HE
targeting GLN metabolism
Treatment Adverse effects Comment
GLN restriction ↓ GLN ? Applicable only in artificial diet
formulas.
Glutamate ↑ GLN Favorable effect only temporary.
α-KG ↓ BCAA? BCAA levels should be monitored.
BCAA ↑ GLN More effective in patients with BCAA
deficiency?
Phenylbutyrate ↓ BCAA and GLN BCAA and GLN levels should be
monitored.
GA inhibitors Impaired GLN catabolism by
enterocytes and immune cells.
Adverse effect on intestine and
immune system?
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muscle, brain, and likely the lungs. Enhanced GLN produc-
tion may exert beneficial effects on immune system and gut
barrier function in addition to its ability to detoxify ammonia.
Conversely, adverse effects may be observed in the brain
(swelling of astrocytes and altered neurotransmission) and in
skeletal muscle (catabolism of BCAA).
The majority of GLN released from the skeletal muscle and
the brain to the circulation is catabolized in enterocytes and
the kidneys back to the ammonia, which, in the case of liver
injury, escapes detoxification to urea, appears in peripheral
blood, and exerts stimulatory effects on GLN synthesis in the
skeletal muscle and brain as noted above. Enhanced GLN-
ammonia cycling among tissues can be seen as a vicious cycle
in which enhanced ammonia detoxification to GLN in skeletal
muscle and in the brain leads to enhanced GLN catabolism to
ammonia in enterocytes and the kidneys, and to subsequent
rise in ammonia levels in the blood (Fig. 3).
The alterations in GLN metabolism induced by liver injury
are sensitive to various nutritional and pharmacological inter-
ventions that may be exploited in the prevention and treatment
of HE. Unfortunately, targeting only one ammonia-lowering
mechanism, such as enhancing GLN synthesis (BCAA), sup-
pressing ammonia production (GA inhibitors and α-
ketoglutarate), and/or promoting GLN elimination (phenyl-
butyrate) may exert substantial adverse effects (Table 1).
Theoretically, the problem of adverse side effects of indi-
vidual ammonia-lowering strategies can be avoided by using a
combination tailored to the specific needs of each patient.
Rational combinations in cirrhotic patients with high am-
monia and low BCAA levels might be BCAA (correction of
BCAA deficiency and stimulation of ammonia detoxification
to GLN), α-KG (suppression of GLN breakdown to ammonia
in the gut and substitution of α-KG consumed in synthesis of
glutamate), and phenylbutyrate (increase in GLN removal). In
patients with acute liver failure, combine GA inhibitors and
phenylbutyrate with α-KG (α-KG may replace GLN as an
energy substrate and thus avoid adverse effects of GA inhib-
itors on the function of intestinal and immune cells). BCAA
levels in patients with acute injury are normal or even in-
creased, and their enhanced intake should be avoided.
Favorable effects of ammonia-lowering strategies have
been reported in urea cycle disorders (Brusilow 1991; Enns
et al. 2007) and in liver cirrhosis (Walshe 1953; McGuire et al.
2010). However, the use of ammonia-lowering strategies has
not been found to be effective enough in patients with acute
liver failure (Acharya et al. 2009; Bémeur and Butterworth
2013). In acute liver failure, there is evidence of a robust
neuroinflammatory response characterized by microglial acti-
vation and increased brain production of pro-inflammatory
cytokines that act synergistically with ammonia in pathogen-
esis of HE (Bémeur and Butterworth 2013). Systemic inflam-
matory response and signs of neuroinflammation occur also in
chronic liver failure (Butterworth 2011). Therefore, careful
studies are needed to evaluate the effects of combining of
ammonia-lowering strategies with therapies reducing neuro-
inflammation such as antibiotics, N-acetylcysteine, indometh-
acin, etanercept, and minocycline.
In conclusion, recent discoveries about the role of activated
GLN-ammonia cycling among tissues in the pathogenesis of
HE are opening new treatment options focused on GLN
metabolism that might be combined with the classical
methods of inhibiting ammonia production by bacteria in the
colon. An important task for clinical researchers seems to be
performing well-conducted trials that would suggest treatment
strategies that are most likely to succeed. Beside the effects on
ammonia levels and HE development, special attention should
be given to their potential adverse effects on GLN and BCAA
homeostasis that may negate their favorable effects.
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